There is limited experience in the mobilization of peripheral blood progenitor cells (PBPC) in children and the optimal method for PBPC mobilization is unknown. The present study was conducted to ascertain whether mobilization with G-CSF + GM-CSF (group I) provides some advantage over G-CSF alone (group II) in terms of collected CD34
Over the past decade, several reports have shown that mobilized peripheral blood progenitor cells (PBPC) can be used for autologous transplantation in pediatric patients. [1] [2] [3] Correspondence: Dr L Madero, Bone Marrow Transplantation Unit, Hospital Niño Jesús, Av. Menéndez Pelayo, 65, 28009 Madrid, Spain Received 2 March 2000; accepted 11 May 2000 Chemotherapy and/or single or multiagent growth factor administration have been utilized for PBPC mobilization in adults. [4] [5] [6] [7] [8] [9] However, the optimal method for PBPC mobilization remains unknown. Several studies have utilized G-CSF alone, 7, 10 GM-CSF alone, 10 and combinations with interleukin-3 (IL-3) 10 or stem cell factor (SCF) 11 to mobilize progenitor cells into peripheral blood. A recent study has shown that PBPC mobilization with stem cell factor plus filgrastrim in high risk cancer patients is superior to filgrastrim alone. 12 There is less experience in children, although some studies have demonstrated that PBPC collected following mobilization with G-CSF is effective in reconstituting hematopoiesis after myeloablative therapy. 5, 13, 14 Since it has been reported that the use of GM-CSF and G-CSF either alone or in combination could improve the quality of the PBPC collected 10 and in vitro studies have demonstrated synergy between GM-CSF and G-CSF, 15 we conducted a phase III study to evaluate the results achieved with mobilization using GM-CSF + G-CSF in one group of children with cancer vs mobilization with G-CSF alone in another group.
The results of mobilization were evaluated according to the characteristics of the apheresis products and data on hematological recovery. Furthermore, costs of transplantation were analyzed in both groups of patients. To our knowledge, no study of this type has been conducted in children undergoing PBPC transplantation.
Patients and methods

Study population
Patients were children under 16 with hematological neoplasias or solid tumors who underwent PBPC transplantation at the BMT Unit between January 1997 and January 1999. The main characteristics of the patients are shown in Table 1 . Parents' informed consent was obtained in all cases.
Study design
This was a prospective, non-randomized, consecutive, controlled trial. Patients were consecutively assigned to receive G-CSF alone or the combination of G-CSF and GM-CSF. 
PBPC mobilization
The patients in one group were assigned to G-CSF (12 g/kg/day) given subcutaneously for 4-5 days and GM-CSF (5 g/kg/day) given subcutaneously for 4-5 days before starting PBPC apheresis. The other group of patients received G-CSF alone (12 g/kg/day) subcutaneously 4-5 days before starting PBPC apheresis.
PBPC collection
Collections by large-volume leukaphereses (LVL) were performed on day +5 after mobilization by a Cobe Spectra blood cell separator (Cobe BCT, Lakewood, CO, USA). The target number of CD34 + cells was 5 ϫ 10 6 /kg, although a minimum of 1 ϫ 10 6 /kg CD34 + cells was considered sufficient for transplantation. The number of blood volumes required to be processed in each apheresis was estimated based on our previous experience. If the yield for a single apheresis was considered insufficient, the apheresis was continued until the CD34 + cell target dose was achieved or it was repeated on subsequent days. 13 The final product containing 10% DMSO was frozen using a computercontrolled freezer and stored in liquid nitrogen at −196°C.
Conditioning regimen and supportive therapy
Patients received myeloablative regimens ( Table 2 ). All patients had a central venous line and were nursed under strict protective isolation in barrier nursing units with HEPA-filtered air. Infectious prophylaxis was provided using cotrimoxazole. On day 0 collected cells were infused after rapid thawing at 37°C. All patients received G-CSF (10 g/kg/day) starting on day +1 until an absolute neutrophil count (ANC) Ͼ1.0 ϫ 10 9 /kg was maintained for 2 consecutive days. Empiric i.v. antibiotic treatment was initiated as soon as fever of Ͼ38°C occurred. Amphotericin (1 mg/kg/day) was added if fever and neutropenia continued for 4-5 days after antibiotics were started. Blood products were infused to maintain the hematocrit Ͼ25% and the platelet count Ͼ20 ϫ 10 9 /l. All blood-derived trans- fusion products were irradiated prior to use. After hospital discharge patients were investigated every 15 days until day +100 by clinical examination, a total blood count and biochemical parameters.
Definitions
Neutrophil recovery was defined as the number of days taken to achieve an ANC Ͼ0.5 ϫ 10 9 /l for 3 consecutive days. Platelet recovery was defined as the time taken to achieve Ͼ20 ϫ 10 9 /l without requiring transfusion. Hospital stay was defined as the number of days from day 0 to day of hospital discharge.
Economic analysis
Each patient's cost from mobilization to day +100 was calculated according to inpatient and outpatient information. We included direct expenditure for hospitalization (including medical and paramedical expenditures), conditioning regimen (including total body irradiation) apheresis, supportive care, laboratory tests and radiological procedures. Drugs and single-use material costs were valued at the cost price of the institution. Blood product costs were obtained from the transfusion Regional Center Laboratory and radiology-derived costs were obtained from the institution. Daily hospitalization cost for the university hospital was obtained from the Spanish Health Department. Costs were calculated in US dollars.
Statistical analysis
Normally distributed data are presented as mean Ϯ standard deviation. Non-normally distributed data are presented as median and range. Differences were compared using the Mann-Whitney test. The Stata software program (Stata Corporation, College Station TX, USA) was used for statistical analysis.
Results
Patients' characteristics
Forty-two children were included in the study. Of these, 21 were assigned to G-CSF + GM-CSF (group I) and 21 to G-CSF alone (group II) for PBPC mobilization. Patient characteristics and treatment are shown in Tables 1 and 2 . There were no statistically significant differences in characteristics between the two groups.
All patients were evaluable for neutrophil engraftment with the exception of one patient in group I with CNS germinal tumor who did not achieve platelet engraftment and died on day +15 due to multiorgan failure.
Apheresis and PBPC collection
The mean number of aphereses was 1.5 Ϯ 0.5 in group I and 1.2 Ϯ 0.46 in group II (NS). The mean number of CD34 + cells was 3.8 ϫ 10 6 Ϯ 4.03/kg in group I and 4.2 Ϯ 5.4 in group II (NS). The mean number of total blood volumes (TBV) processed was 4.4 Ϯ 1.5 in group I and 4.3 Ϯ 1.5 in group II (NS). The mean duration of the procedure was 276 Ϯ 74.1 min in group I and 286.7 Ϯ 75.9 min in group II (NS), and the inlet flow was 45.1 Ϯ 12 ml/min in group I and 39.5 Ϯ 15.1 ml/min in group II (NS).
Toxicity related to PBPC collection was acceptable. Minor symptomatic episodes of hypocalcemia manifested as anxiety and perioral tingling were observed in one procedure in group II and in another one in group I and resolved on calcium infusion. No allergic reactions were observed. After the procedure cytopenia was observed in most patients, with moderate and reversible thrombocytopenia in all patients. None required platelet transfusion.
Hematopoietic recovery
No significant differences in the neutrophil and platelet engraftment probability were observed between the two groups and the clinical values analyzed are shown in Table 3 . 
Mortality related to high-dose chemotherapy
One patient in group I with CNS germinal tumor died on day +15 from multiorgan failure. Two patients in group II with a diagnosis of medulloblastoma and PNET with progressive disease died due to multiorgan failure and respiratory distress on days +25 and +46, respectively.
Economic analysis
The mean overall cost of group II was not statistically significant from that group I (US$ 9521 Ϯ 330 vs US$ 10 201 Ϯ 1028, P = NS). The distribution of resources used are shown in Table 4 . The cost of mobilization was significantly higher in group I than in group II (US$ 670 Ϯ 349 vs US$ 395 Ϯ 202, P Ͻ 0.003). Conditioning regimen costs were similar in both groups. The costs related to the posttransplant period were similar in both groups (Table 4) .
Discussion
Mobilized peripheral blood is now the main hematopoietic progenitor cell source for cellular support following myeloablative chemotherapy. We 3,14 and others 16, 17 have demonstrated that PBPC collection is safe in pediatric patients, even in very low weight children. In our study we collected PBPC by LVL after we had demonstrated that LVL can be safely and easily performed in children. 18, 19 We found no significant differences in PBPC collection data (total number of apheresis procedures required, number of TBV processed, inlet flow and duration of the procedure) between the groups.
PBPC as cellular support results in a more rapid hematopoietic recovery than bone marrow mainly due to the greater number of hematopoietic progenitor cells infused. [20] [21] [22] Currently the number of CD34
+ cells in stem cell collections is considered to be the best predictor for the speed of neutrophil and platelet engraftment after PBPCT. 23, 24 However, the optimal procedure for PBPC mobilization in pediatric patients has not yet been determined because data on the engraftment kinetics are scanty. Our previously reported data show that a CD34 + cell dose of 5.0 ϫ 10 6 /kg may be sufficient to ensure rapid neutrophil and platelet recovery in pediatric patients mobilized by G-CSF. A minimum dose of 1 ϫ 10 6 /kg CD34 + cells may be sufficient to ensure rapid neutrophil engraftment but is insufficient for platelet recovery. 13 To optimize mobilization and to obtain a greater number of CD34
+ cells, we simultaneously administered GM-CSF and G-CSF. However, the number of CD34 + cells collected was similar for both groups: 3.8 ϫ 10 6 /kg CD34 + cells for group I and 4.2 for group II. Data for hematological recovery and the clinical values derived from them were not statistically significant between the groups. We found no differences in the time to ANC Ͼ0.5 ϫ 10 9 /l and platelets Ͼ20 and 50 ϫ 10 9 /l in both groups. These findings are similar to those reported by Spitzer et al, 25 who also found no differences in hematological recovery, although a recent abstract has reported that concurrent GM-CSF and G-CSF administration appears to produce superior yields of PBPC than those achieved by G-CSF alone. 26 Our study is of interest for mobilization in children because it is the first study conducted on pediatric patients with the same distribution of disease in both groups, who were given a similar conditioning regimen and who received the same growth factor post transplantation (G-CSF).
The present study also includes an economic comparison of the cost of both groups from the perspective of the Spanish health care system. Analysis of different resource areas showed mobilization costs were significantly more expensive in group I than in group II. Supportive care (including blood products, parenteral nutrition, inotropics, morphics, antibiotics and growth factors) and monitoring costs were not significantly different. However, there were no significant differences in the overall cost.
Although our overall cost for PBPCT is lower than in other reports on the subject, [27] [28] [29] [30] it is very difficult to establish comparisons because of differences in institutions, protocols, diseases and salaries for medical and paramedical personnel. The lower cost may be due to the following factors: (1) the mean weights of our patients were 34 and 36 kg for group I and group II, respectively; (2) we performed single apheresis in most of the patients; and (3) we did not evaluate indirect cost.
From the present data, we conclude that PBPC mobilization with G-CSF + GM-CSF in children does not enhance hematological recovery in comparison with mobilization using G-CSF alone. However, the combination of G-CSF + GM-CSF does not increase the overall cost of transplantation. Further studies on different growth factors are warranted in order to determine the optimum strategy for mobilization to enhance hematopoietic recovery.
